Azzad Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Azzad Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-22,856	Closed	-$1.41M	–	409
2022 Q3	$1.41M	Buy	22,856 +3,146	+16%	+$220K	0.14%	212
2022 Q2	$1.57M	Buy	19,710 +615	+3%	+$58.2K	0.16%	197
2022 Q1	$2.01M	Buy	19,095 +2,529	+15%	+$246K	0.29%	135
2021 Q4	$1.79M	Sell	16,566 -102	-0.6%	-$11.1K	0.24%	163
2021 Q3	$1.83M	Buy	16,668 +1	+0%	+$104	0.27%	152
2021 Q2	$1.56M	Sell	16,667 -1	-0%	-$92	0.23%	169
2021 Q1	$1.53M	Buy	+16,668	New	+$1.41M	0.25%	163

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Azzad Asset Management's HZNP Position: Q4 2022 in Review

Azzad Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 22,856 shares — an estimated $1.41M sold.

Azzad Asset Management first reported a position in HZNP in Q1 2021 and held it in 7 quarters. The position peaked at $2.01M in Q1 2022. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Azzad Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Azzad Asset Management sold 22,856 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $1.41M.
Azzad Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 7 quarters.
Azzad Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.01M in Q1 2022.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Azzad Asset Management's 13F filing for Q4 2022, filed 1 Apr 2024.